Category: Endocrinology / Acute Internal Medicine
Reading Time: 6 minutes
Introduction: More Than Just a Glucose Reading
In 2026, the management of diabetes in the acute receiving ward has evolved from “glucose-centric” to “comorbidity-centric.” We are no longer just chasing a target HbA1c; we are managing a complex interplay of cardiovascular risk, renal protection, and metabolic stability.
Following the Medicine24 sessions on “Tricky Glycaemic Control,” this blog explores how to apply the latest 2026 international guidelines to the patient sitting in your Assessment Unit right now.
1. The “Cardio-Renal-Metabolic” Triple Crown
Google’s 2026 algorithm rewards “Topical Authority.” This section highlights the shift in first-line therapy.
The 2026 Update: Both the AACE and NICE 2026 updates now prioritize GLP-1 receptor agonists and SGLT2 inhibitors as early-intervention “disease modifiers,” regardless of the baseline HbA1c, for patients with high cardiovascular or renal risk.
The Acute Challenge: When a patient is admitted with an acute illness (e.g., sepsis), when do we pause these “miracle drugs”?
Medicine24 Tip: Remember the “Sick Day Rules.” Pause SGLT2is immediately in any patient at risk of dehydration or euglycaemic DKA (Diabetic Ketoacidosis).
2. DKA with Normal Sugars: The Euglycaemic Trap
With the widespread use of SGLT2 inhibitors, we are seeing more cases of Euglycaemic DKA (EuDKA).
The Diagnosis: The patient has a metabolic acidosis (pH <7.3, Bicarb <15) and high ketones, but their blood glucose is <11.0 mmol/L.
The Action: Do not wait for high blood sugar to start the DKA protocol. Early IV fluid resuscitation and fixed-rate insulin are still the gold standard, but you must start 10% Dextrose earlier to prevent hypoglycemia.
3. The 2026 Metabolic Comparison: Once-Weekly vs. Daily Insulin
One of the most debated topics at the recent conference was the introduction of Once-Weekly Insulins for Type 2 Diabetes.
| Feature | Standard Basal Insulin (Daily) | Once-Weekly Insulin (2026 Update) |
| Adherence | Requires daily commitment. | Improved patient compliance. |
| Acute Mgmt | Easier to “stop/start” during fasting. | Requires careful transition to IV insulin. |
| Hypo Risk | Standardized. | Slightly higher in frail elderly; requires caution. |
| Medicine24 Verdict | Better for the unstable acute patient. | The future of chronic primary care. |
4. Obesity as a Primary Medical Diagnosis
As Professor Hany Eteiba highlighted in his vision for the College, we must treat obesity as a chronic disease. The 2026 “Obesity Pillars” discussed at Medicine24 focus on:
Metabolic Satiety: Using GLP-1s to reset the “brain-gut” axis.
Lean Mass Preservation: Ensuring patients maintain muscle while losing fat.
The Acute Benefit: Every 5% weight loss significantly reduces the risk of the “Acute Cardiac Take.”
Conclusion: Precision Metabolism
The 2026 metabolic landscape is exciting but complex. By staying aligned with the Medicine24 curriculum, you ensure that your diabetes management is not just “safe,” but “future-proof.” We aren’t just treating the sugar; we are protecting the heart and kidneys for the long term.
Download the Checklist: Get our 2026 “Sick Day Rules” PDF for SGLT2i and GLP-1 Users.
